产品中心Cell Resources
联系我们CONTACT US
- 400-999-210024小时服务热线
产品概述
名称 | NK-92 (人恶性非霍奇金淋巴瘤患者的自然杀伤细胞) (STR鉴定正确) |
别称 | NK92; Natural Killer-92; NK-92.05; Neukoplast; aNK |
种属 | 人类 |
生长特性 | 悬浮细胞 |
细胞形态 | 淋巴母细胞样 |
冻存条件 | 冻存液:90%FBS+10%DMSO 温度:液氮 |
培养方案A(默认) |
生长培养基:
MEMα+0.2mM Inositol+0.1mM β-mercaptoethanol+0.02mM Folic Acid+100-200U/mL recombinant IL-2+12.5% HS+12.5% FBS+1% P/S
培养条件:
气相:空气,95%;CO2,5%, 温度:37℃
|
推荐传代比例 | 5×10^5-1×10^6cells/mL |
推荐换液频率 | 2-3次/周 |
注意事项 | 该细胞为悬浮细胞,请注意离心收集细胞悬液;请勿直接倒掉细胞培养液。 |
背景描述 | NK-92细胞是从一位患有急进性非霍奇金淋巴瘤的50岁白人男性外周血单核细胞衍生来的一株IL-2依赖型NK细胞株。NK-92细胞对很多恶性细胞有细胞毒性;铬释放试验显示它能杀死K562细胞和Daudi细胞。NK-92细胞(经过照射以防止增殖)可以有效地用于血液中白血病的体外免疫清扫而不危及血细胞的功能。NK-92细胞有以下特征:CD2、CD7、CD11a、CD28、CD45、CD54表面标记阳性;CD1、CD3、CD4、CD5、CD8、CD10、CD14、CD16、CD19、CD20、CD23、CD34和HLA-DR表面标记阴性。 |
年龄(性别) | 男性;50岁 |
组织来源 | 外周血 |
细胞类型 | 肿瘤细胞 |
肿瘤类型 | 淋巴瘤细胞 |
生物安全等级 | BSL-2 |
倍增时间 | ~40-50 hours |
保藏机构 | ATCC; CRL-2407 DSMZ; ACC-488 |
STR鉴定
-
STR位点信息
Amelogenin X,Y CSF1PO 11,12 D2S1338 19,20 D3S1358 15 D5S818 12,13 D7S820 10,11 D8S1179 12 D13S317 9,12 D16S539 11,12 D18S51 12,17 D19S433 14,15 D21S11 31.2,32 FGA 20,22 PentaD 10,12 PentaE 12 TH01 6,9.3 TPOX 8 vWA 18 D6S1043 11,12 D12S391 19 D2S441 14 -
STR鉴定图
参考文献
-
L-kynurenine induces NK cell loss in gastric cancer microenvironment via promoting ferroptosis(2023/03/01)
作者:Jianxin Cui, Xianhui Xu, Tao He
期刊:JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
DOI:10.1186/s13046-023-02629-w
影响因子 :11.300
引用产品:CL-0530
-
MMP-2 Inhibitor-Mediated Tumor Microenvironment Regulation Using a Sequentially Released Bio-Nanosystem for Enhanced Cancer Photo-Immunotherapy(2022/09/08)
作者:Huifang Liu, Dongqin Lei, Jiong Li
期刊:ACS Applied Materials & Interfaces
影响因子 :9.500
引用产品:CL-0530
-
CD44 3-Untranslated Region Functions as a Competing Endogenous RNA to Enhance NK Sensitivity of Liver Cancer Stem Cell by Regulating ULBP2 Expression(2019/06/04)
作者:Jun Weng, Xu Han, Kaiyu Liu
期刊:International Journal of Biological Sciences
影响因子 :9.200
引用产品:CL-0530
-
Therapeutic effects against high-grade glioblastoma mediated by engineered induced neural stem cells combined with GD2-specific CAR-NK(2023/07/07)
作者:Weihua Liu, Yu Zhao, Zhongfeng Liu
期刊:CELLULAR ONCOLOGY
DOI:10.1007/s13402-023-00842-5
影响因子 :6.600
-
NK92 cells and peripheral blood NK cells respond oppositely upon dasatinib treatment(2024/02/15)
作者:Fengqi Li, Zhongyi Wang, Dongpeng Zheng
期刊:IMMUNOLOGY
影响因子 :6.400
引用产品:CL-0530
-
Enhanced NK cell activation via eEF2K-mediated potentiation of the cGAS–STING pathway in hepatocellular carcinoma(2024/02/05)
作者:Yan Xu, Fang Sun, Yuying Tian
期刊:INTERNATIONAL IMMUNOPHARMACOLOGY
DOI:10.1016/j.intimp.2024.111628
影响因子 :5.600
引用产品:CL-0530
-
Assessing immune hepatotoxicity of troglitazone with a versatile liver-immune-microphysiological-system(2024/05/30)
作者:Quanfeng Deng, Youlong Yang, Yuangui Liu
期刊:Frontiers in Pharmacology
DOI:10.3389/fphar.2024.1335836
影响因子 :5.600
引用产品:CL-0530
-
Enhanced Proinflammatory Cytokine Production and Immunometabolic Impairment of NK Cells Exposed to Mycobacterium tuberculosis and Cigarette Smoke(2022/01/05)
作者:Yafei Rao, Xiaoyan Gai, Yanqing Le
期刊:Frontiers in Cellular and Infection Microbiology
影响因子 :5.500
引用产品:CL-0530
-
Platelet-derived major histocompatibility complex class I coating on Treponema pallidum attenuates natural killer cell lethality(2024/05/14)
作者:Qiuyan Xu, Xinqi Zheng, Weiming Ye
期刊:Virulence
DOI:10.1080/21505594.2024.2350892
影响因子 :5.200
引用产品:CL-0530
-
PKCι regulates the expression of PDL1 through multiple pathways to modulate immune suppression of pancreatic cancer cells(2021/8/8)
作者:Hongmei Zhang, Yue Zhu, Junli Wang
期刊:Cellular Signalling
DOI:10.1016/j.cellsig.2021.110115
影响因子 :4.800
引用产品:CL-0530
-
Transcription factor Sp1 is upregulated by PKCι to drive the expression of YAP1 during pancreatic carcinogenesis(2021/4/17)
作者:Jinhe Yang, Junli Wang, Hongmei Zhang
期刊:Carcinogenesis
影响因子 :4.700
引用产品:CL-0530
-
Development of TSHR-CAR NK-92 Cells for Differentiated Thyroid Cancer(2024/04/24)
作者:Jiahui Zhou, Chengcheng Zhang, Weibo Mao
期刊:MOLECULAR AND CELLULAR ENDOCRINOLOGY
影响因子 :4.100
引用产品:CL-0530
-
SHFM1 deficiency suppresses esophageal squamous cell carcinomas progression via modulating NF‑κB signaling and enhancing nature killer cell‑mediated tumor surveillance(2023/03/17)
作者:Yijuan Wu, Zhiyu Wang, Shengmian Li
期刊:Experimental and Therapeutic Medicine
影响因子 :2.700
FAQs
Q:{{item.question}}
A:
产品资料
识别码示意图